share_log

Akso Health Group (NASDAQ:AHG) Delivers Shareholders Stellar 271% Return Over 1 Year, Surging 36% in the Last Week Alone

Akso Health Group (NASDAQ:AHG) Delivers Shareholders Stellar 271% Return Over 1 Year, Surging 36% in the Last Week Alone

Akso Health Group(納斯達克股票代碼:AHG)在1年內爲股東帶來了271%的驚人回報率,僅在上週就飆升了36%
Simply Wall St ·  01/31 19:58

Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Akso Health Group (NASDAQ:AHG) share price has soared 271% return in just a single year. And in the last month, the share price has gained 111%. In contrast, the longer term returns are negative, since the share price is 32% lower than it was three years ago.

不幸的是,投資是有風險的——公司可以而且確實會破產。但是,當你選擇一家真正蓬勃發展的公司時,你可以 使 超過 100%。例如,阿克索健康集團(納斯達克股票代碼:AHG)的股價在短短一年內就飆升了271%的回報率。而在上個月,股價上漲了111%。相比之下,長期回報率爲負,因爲股價比三年前低32%。

The past week has proven to be lucrative for Akso Health Group investors, so let's see if fundamentals drove the company's one-year performance.

事實證明,過去一週對Akso Health Group的投資者來說是有利可圖的,因此讓我們看看基本面是否推動了該公司一年的業績。

See our latest analysis for Akso Health Group

查看我們對Akso Health Group的最新分析

Akso Health Group wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Akso Health Group在過去十二個月中沒有盈利,我們不太可能看到其股價與每股收益(EPS)之間存在很強的相關性。可以說,收入是我們的下一個最佳選擇。無利可圖的公司的股東通常期望強勁的收入增長。一些公司願意推遲盈利以更快地增加收入,但在這種情況下,人們確實預計收入會有良好的增長。

In the last year Akso Health Group saw its revenue shrink by 87%. So we would not have expected the share price to rise 271%. This is a good example of how buyers can push up prices even before the fundamental metrics show much growth. Of course, it could be that the market expected this revenue drop.

去年,阿克索健康集團的收入減少了87%。因此,我們沒想到股價會上漲271%。這是一個很好的例子,說明買家甚至在基本面指標顯示出大幅增長之前就可以推高價格。當然,可能是市場預期的收入下降。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收入和收入隨時間推移的跟蹤情況(如果您點擊圖片,可以看到更多細節)。

earnings-and-revenue-growth
NasdaqCM:AHG Earnings and Revenue Growth January 31st 2024
納斯達克股票代碼:AHG 收益和收入增長 2024 年 1 月 31 日

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以在這張免費的交互式圖片中看到其資產負債表如何隨着時間的推移而增強(或減弱)。

A Different Perspective

不同的視角

It's nice to see that Akso Health Group shareholders have received a total shareholder return of 271% over the last year. There's no doubt those recent returns are much better than the TSR loss of 13% per year over five years. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Akso Health Group is showing 4 warning signs in our investment analysis , and 3 of those don't sit too well with us...

很高興看到Akso Health Group股東去年獲得的股東總回報率爲271%。毫無疑問,最近的回報遠好於五年內每年13%的股東總收入損失。我們通常更看重短期內的長期表現,但最近的改善可能暗示業務出現了(積極的)轉折點。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。即便如此,請注意,Akso Health Group在我們的投資分析中顯示了4個警告信號,其中3個對我們不太滿意...

Of course Akso Health Group may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,Akso Health Group可能不是最好的買入股票。因此,您可能希望看到這批免費的成長股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論